Stay updated with breaking news from Iontas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Artist Michael Stafford said he is delighted to be unveiling his latest body of work in the Íontas Arts centre in Castleblaney tomorrow eevening. Michael...
Artist Michael Stafford said he is delighted to be unveiling his latest body of work in the Íontas Arts centre in Castleblaney next week. Michael's exhib...
Mar 17 2021 Read 132 Times Human antibodies developers IONTAS and FairJourney Biologics have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. Quell is harnessing the suppressive capacity of Tregs to develop engineered Treg cell therapies to address several conditions of immune dysfunction. Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel of novel target binders, ranging in affinities, to enable Quell to select functional binders for chimeric antigen receptor (CAR) development against undisclosed targets. The collaboration is non-exclusive and further terms of the agreement are not being disclosed.